Access to targeted therapies for lung cancer depends on accurate identification of patients' biomarkers through molecular testing, but survey results published today in the Journal of Thoracic Oncology suggest that many international clinicians are unaware of evidence-based guidelines that support the use of molecular testing.
from News Medical Medical Research News Feed https://ift.tt/2TqlQPF
0 Comments